BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 33435133)

  • 1.
    Voutsadakis IA
    J Clin Med; 2021 Jan; 10(2):. PubMed ID: 33435133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinogenesis of PIK3CA.
    German S; Aslam HM; Saleem S; Raees A; Anum T; Alvi AA; Haseeb A
    Hered Cancer Clin Pract; 2013 Jun; 11(1):5. PubMed ID: 23768168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations in claudin 18 suppressed and non-suppressed gastric adenocarcinomas to guide targeted therapies.
    Voutsadakis IA
    Tissue Barriers; 2024 May; ():2348852. PubMed ID: 38713052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex.
    Deng ZM; Liu L; Qiu WH; Zhang YQ; Zhong HY; Liao P; Wu YH
    PeerJ; 2017; 5():e3216. PubMed ID: 28503373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The landscape of driver mutations in cutaneous squamous cell carcinoma.
    Chang D; Shain AH
    NPJ Genom Med; 2021 Jul; 6(1):61. PubMed ID: 34272401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.
    Duranti S; Pietragalla A; Daniele G; Nero C; Ciccarone F; Scambia G; Lorusso D
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33925884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic crosstalk within the tumor microenvironment of uterine cervical carcinoma: baseline network, iatrogenic alterations, and translational implications.
    De Nola R; Loizzi V; Cicinelli E; Cormio G
    Crit Rev Oncol Hematol; 2021 Jun; 162():103343. PubMed ID: 33930531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical Cancer Immunotherapy: Facts and Hopes.
    Ferrall L; Lin KY; Roden RBS; Hung CF; Wu TC
    Clin Cancer Res; 2021 Sep; 27(18):4953-4973. PubMed ID: 33888488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
    Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
    Huang RSP; Haberberger J; Murugesan K; Danziger N; Hiemenz M; Severson E; Duncan DL; Ramkissoon SH; Ross JS; Elvin JA; Lin DI
    Mod Pathol; 2021 Jul; 34(7):1425-1433. PubMed ID: 33637877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis.
    Horeweg N; Mittal P; Gradowska PL; Boere I; Chopra S; Nout RA
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives.
    Krasniqi E; Barba M; Venuti A; Pizzuti L; Cappuzzo F; Landi L; Carpano S; Marchetti P; Villa A; Vizza E; Giuliano G; Mazzotta M; Marinelli D; Gnignera S; Vincenzoni C; Stranges V; Sergi D; Giordano A; Tomao F; Maugeri-SaccĂ  M; Sanguineti G; Di Lisa FS; Tomao S; Ciliberto G; Vici P
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33917435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment characterization in cervical cancer identifies prognostic relevant gene signatures.
    Peng L; Hayatullah G; Zhou H; Chang S; Liu L; Qiu H; Duan X; Han L
    PLoS One; 2021; 16(4):e0249374. PubMed ID: 33901225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated Analysis of Immune Infiltration Features for Cervical Carcinoma and Their Associated Immunotherapeutic Responses.
    Kang Y; Huang J; Liu Y; Zhang N; Cheng Q; Zhang Y
    Front Cell Dev Biol; 2021; 9():573497. PubMed ID: 33898414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer.
    Chen Y; Lin H; Pi YN; Chen XX; Zhou H; Tian Y; Zhao WD; Xia BR
    Front Oncol; 2021; 11():616530. PubMed ID: 33842318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Systematic Review of MicroRNAs Involved in Cervical Cancer Progression.
    Causin RL; Freitas AJA; Trovo Hidalgo Filho CM; Reis RD; Reis RM; Marques MMC
    Cells; 2021 Mar; 10(3):. PubMed ID: 33803022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic characterisation of cervical cancer and human papillomavirus: new opportunities for precision medicine.
    Franceschi S
    Lancet Oncol; 2021 Apr; 22(4):419-420. PubMed ID: 33794201
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrated analysis of virus and host transcriptomes in cervical cancer in Asian and Western populations.
    Qiu Q; Zhou Q; Luo A; Li X; Li K; Li W; Yu M; Amanullah M; Lu B; Lu W; Liu P; Lu Y
    Genomics; 2021 May; 113(3):1554-1564. PubMed ID: 33785400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis.
    Chen Q; Qiu B; Zeng X; Hu L; Huang D; Chen K; Qiu X
    Cancer Cell Int; 2021 Mar; 21(1):182. PubMed ID: 33766042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.